BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen Y, Liaw Y. Pharmacotherapeutic options for hepatitis B. Expert Opinion on Pharmacotherapy 2016;17:355-67. [DOI: 10.1517/14656566.2016.1118056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Liaw YF. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection. Nat Rev Gastroenterol Hepatol. 2019;16:631-641. [PMID: 31477873 DOI: 10.1038/s41575-019-0197-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
2 Wu DX, Fu XY, Gong GZ, Sun KW, Gong HY, Wang L, Wu J, Tan DM. Novel HBV mutations and their value in predicting efficacy of conventional interferon. Hepatobiliary Pancreat Dis Int 2017;16:189-96. [PMID: 28381384 DOI: 10.1016/s1499-3872(16)60184-4] [Reference Citation Analysis]
3 Boglione L, De Benedetto I, Dodaro V, Chiecchio M, De Nicolò A, Di Perri G, D’avolio A. Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B. Arch Virol. [DOI: 10.1007/s00705-022-05466-y] [Reference Citation Analysis]
4 Shih C, Chou S, Yang C, Huang J, Choijilsuren G, Jhou R. Control and Eradication Strategies of Hepatitis B Virus. Trends in Microbiology 2016;24:739-49. [DOI: 10.1016/j.tim.2016.05.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
5 Liaw YF, Chien RN. Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation". Kaohsiung J Med Sci 2022. [PMID: 35262284 DOI: 10.1002/kjm2.12518] [Reference Citation Analysis]
6 Wu L, Xu W, Li X, Liu Y, Wang L, Zhu S, Yang F, Xie C, Peng L. The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment. Front Pharmacol 2021;12:616858. [PMID: 33716744 DOI: 10.3389/fphar.2021.616858] [Reference Citation Analysis]
7 Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833-51. [PMID: 34297329 DOI: 10.1007/s12072-021-10223-5] [Reference Citation Analysis]
8 Liaw YF. Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift. Hepatol Int. 2019;13:665-673. [PMID: 31559604 DOI: 10.1007/s12072-019-09989-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
9 Hsu CW, Su WW, Lee CM, Peng CY, Chuang WL, Kao JH, Chu HC, Huang YH, Chien RN, Liaw YF. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. J Formos Med Assoc. 2018;117:588-597. [PMID: 29456079 DOI: 10.1016/j.jfma.2017.12.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
10 Jeng WJ, Chen YC, Chien RN, Sheen IS, Liaw YF. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2018;68:425-434. [PMID: 29108132 DOI: 10.1002/hep.29640] [Cited by in Crossref: 100] [Cited by in F6Publishing: 88] [Article Influence: 25.0] [Reference Citation Analysis]
11 Zhang JF, Xiong HL, Cao JL, Wang SJ, Guo XR, Lin BY, Zhang Y, Zhao JH, Wang YB, Zhang TY, Yuan Q, Zhang J, Xia NS. A cell-penetrating whole molecule antibody targeting intracellular HBx suppresses hepatitis B virus via TRIM21-dependent pathway. Theranostics. 2018;8:549-562. [PMID: 29290826 DOI: 10.7150/thno.20047] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]